Navigation Links
The International Myeloma Foundation Says New Clinical Trial,Results Could Improve Survival While Reducing Side Effects For Many,Patients

the IMF, added, "These findings may also have wider implications for cancer treatments because they challenge the traditional notion that patients should be treated with the highest dose of medicine they can tolerate. Now we have evidence that in some situations, less may be more when treating cancer."

REVLIMID from the Celgene Corporation is the newest of the group of medicines called novel therapies that have significantly improved the outlook for patients with myeloma. Preliminary analysis of the ECOG data shows patients taking REVLIMID plus low dose dexamethasone had a 96% survival rate after one year with a reduced risk of side effects. One year survival for those taking the higher dose of dexamethasone was 86%. The findings are expected to prompt review of the dexamethasone dose when paired with other medications used in myeloma such as THALOMID(R), and discussions are already underway to change dosing in other clinical trials using REVLIMID with dexamethasone.

"This is a very exciting finding for patients," said Michael Katz, who, as a 16-year myeloma survivor, is a vice president of the IMF and co-chair of ECOG's Patient Representatives Committee. "When ECOG's patient representatives proposed adding a lower dose 'dex' arm to this trial, we were just looking for a way to make the treatment more tolerable; we never expected that the outcome for patients would actually improve. We are grateful to all of the patients who participated and to ECOG Group chair, Dr. Robert Comis and Myeloma Committee chair, Dr. Vincent Rajkumar, for supporting the notion of testing lower doses and making this trial happen."

Mr. Katz continued: "This result sends an important signal to physicians that maximum tolerated dose is not always the right answer when treating patients with cancers like myeloma that are incurable, but highly treatable."

Myeloma, also called multiple myeloma, is a cancer of the bone marrow that affects production of red cells, white
'"/>




Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
(Date:9/19/2014)... Sept. 19, 2014  Lpath, Inc. (NASDAQ: ... lipid-targeted therapeutics, announced today that it has entered ... of common stock and 3,605,042 unregistered warrants in ... for one registered share of common stock and ... of common stock will be $3.475.  The warrants ...
(Date:9/19/2014)... Sept. 19, 2014  Over 200 runners participated in ... Benefit the Radiation Oncology Institute (ROI), hosted by Radiation ... Gate Park in San Francisco.  "Donations ... CEO of Radiation Business Solutions, "but at this ... over $70,000 for the ROI this year. This surpasses ...
(Date:9/19/2014)... Austria , September 19, 2014 ... control persist for many years in people with diabetes ... produce major long term benefits for the kidneys." ... in patients with type 2 diabetes leads to persistent ... usual care. The global study has found ...
Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... pressure for a new product to succeed at launch ... sector facing pipeline deficits, patent expirations and increasing development ... product launch leaders are looking to guard against uncertainty ... regulatory and marketplace challenges. To that ...
... Calif., March 4, 2011 Cardica, Inc. (Nasdaq: ... surgical cutting and stapling device developed by Cardica has ... the multi-step CE marking process, Cardica has obtained a ... manufacturing processes.  With this certification, after successful completion of ...
Cached Medicine Technology:Pharmaceutical Launch Excellence Services Delivers Market Entry Road Map 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 3Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 4
(Date:9/19/2014)... (PRWEB) September 19, 2014 BearCom, ... solutions, today detailed the key role played by ... radios in the healthcare industry. , “In ... patient care – and in emergency situations, can ... between life and death,” said Hugh Johnston, Product ...
(Date:9/19/2014)... 2014 Hastings and Hastings, a discount accident ... industry, announces a record number of visitors to its new ... of serious injury cases as well as auto accident cases ... related accident cases and others. Having served the state of ... the test of time when it comes to dedicated and ...
(Date:9/19/2014)... New York (PRWEB) September 19, 2014 ... a transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that ... court next month, Bernstein Liebhard LLP reports. According ... Dallas District Court, the company asserts that claims involving ... Texas Civil Practice and Remedies Code, a section of ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Although ... key health benefits, most middle-aged and older adults ... type of exercise, according to new research. ... the muscle-strengthening recommendations set by the Department of ... Strength is essential for promoting health and ...
(Date:9/19/2014)... 19, 2014 Lipitor lawsuits ( http://www.thelipitorlawsuit.com/ ... patients to develop Type 2 diabetes continue to move ... U.S. District Court, District of South Carolina, Bernstein Liebhard ... September 12, 2014, discovery is underway and moving forward ... that Pfizer, Inc., the manufacturer of Lipitor, has produced ...
Breaking Medicine News(10 mins):Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 3Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 4Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3
... a significant role in controlling blood sugar, according to a ... aimed at the molecules in the brain // which respond ... of the condition. The brain has a significant role to ... Michael Schwartz. ,The experiments were conducted on ...
... in the haemagglutinin protein of the bird flu virus. Haemagglutinin ... host and the variability // and fragmentation of this antigen ... if a person or bird is infected with two viral ... fragmented and during annealing there are chances of joining of ...
... the field of life sciences and biotechnology. Staf ... Biosciences, told a seminar that the country has tremendous potential ... are starting with an R&D project in tuberculosis, in collaboration ... at the seminar organized here by the Belgo-Indian Chamber of ...
... flu situation in the light of the new cases in Turkey, ... allot more antiviral pills to Asia and provide the necessary aid ... ,Roche said that it was currently in talks with the ... medicine, which is thought to be the best antidote to the ...
... blocking of the leptin hormone which is mostly produced in ... sclerosis (MS), according to// Italian researchers. Giuseppe Matarese and ... neutralization may be a possible way to both prevent and ... a critical role in the regulation of food intake, metabolism, ...
... A new study was conducted by Professor Lee Kennedy and ... the growing obese// population in North Queensland. ,The ... population but none has been conducted on the queenslanders. Research ... living in the tropical evironment. But a knoweledge of how ...
Cached Medicine News:Health News:Europe Seeks Indian Expertise 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: